SCHEMBL6098042

SCHEMBL6098042

COc1cc2c(Nc3cc(O)c(Cl)cc3F)cnnc2cc1OCCCN1CCOCC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.72
FLT1 P17948 8/20 0.72
EGFR P00533 7/20 0.56
FGFR1 P11362 7/20 0.56
FLT4 P35916 4/20 0.56
SRC P12931 7/20 0.54
ERBB2 P04626 2/20 0.54
RET P07949 2/20 0.54
ABL1 P00519 2/20 0.54
CIT O14578 1/20 0.54
GAK O14976 1/20 0.54
EPHB6 O15197 1/20 0.54
ABCC4 O15439 1/20 0.54
DAPK3 O43293 1/20 0.54
RIPK2 O43353 1/20 0.54
NR1I2 O75469 1/20 0.54
RPS6KA4 O75676 1/20 0.54
STK17B O94768 1/20 0.54
STK10 O94804 1/20 0.54
PRKD3 O94806 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097907 0.93 FLT1 (0.75) KDRFLT1EGFRFGFR1FLT4
SCHEMBL6097412 0.91 KDR (0.58) KDRFLT1EGFRFGFR1FLT4
SCHEMBL6431449 0.88 FLT1 (0.71) KDRFLT1EGFRFGFR1FLT4
Hydrochloric Acid SCHEMBL6434749 0.87 FLT1 (0.69) KDRFLT1EGFRFGFR1FLT4
Hydrochloric Acid SCHEMBL6098444 0.86 KDR (0.72) KDRFLT1EGFRFGFR1FLT4
SCHEMBL7211048 0.85 EGFR (0.78) KDRFLT1EGFRFGFR1FLT4
SCHEMBL6430832 0.84 FLT1 (0.72) KDRFLT1EGFRFGFR1FLT4
SCHEMBL6097880 0.84 KDR (1.00) KDRFLT1EGFRFGFR1FLT4
SCHEMBL6096842 0.84 FLT1 (0.61) KDRFLT1EGFRFGFR1FLT4
Hydrochloric Acid SCHEMBL6435450 0.83 FLT1 (0.71) KDRFLT1EGFRFGFR1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087602-B2 Cinnoline derivatives and use as medicine ASTRAZENECA UK LIMITED (GB) 2006-08-08 US disclosed
EP-0888310-B1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ASTRAZENECA AB (SE) 2005-09-07 EP disclosed
US-20030199513-A1 Cinnoline derivatives and use as medicine ZENECA LIMITED 2003-10-23 US disclosed
US-6514971-B1 For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans ZENECA LIMITED (GB) 2003-02-04 US disclosed
EP-0888310-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1999-01-07 EP disclosed
WO-1997034876-A1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ZENECA LIMITED (GB) 1997-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199513-A1 Cinnoline derivatives and use as medicine VEGFA, CNR1, CCR7 KDR 13/4885FLT1 5/4885EGFR 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.